Determining if your HUB should be insourced, outsourced, or a hybrid of those two options is a big decision. And finding the right answer c

While the norm is to view an audit as a stressful, time-consuming experience, audits can paint a picture not visible to the naked eye and ar

Archbow's experience with program migrations has taught us what to anticipate, how to formulate realistic expectations, and where to fin

With the right approach, a good team, and a realistic timeline, pharma companies can successfully support their patients in new and exciting

Is your pharma company looking for new ways to drive better outcomes? Try building better patients.

Anyone working in oncology needs to be up to speed on these 10 takeaways from the 2018 ABVCC Summit - from the International Pricing Index t

When market access plans fall short, manufacturers can lose patients, physician satisfaction, and ultimately, revenue. Avoid that with this

Poor quality within a HUB can lead to delays in patient treatment, loss of prescriber confidence, and users seeking competitive therapeutic

When asked the big question, "How do I know if my pharma patient access program needs to be optimized?" we share this list.

Tami Stowe has been operationalizing pharma access programs for more than 18 years. Because her career has evolved alongside our industry&#3

PharmaDCX, or Pharma Digital Customer Experience, is the integration of digital technology into all areas of business, resulting in fundamen

New Archbow team member, Justine Hughes, shares five priceless lessons she's learned while managing the frontlines of pharma patient acc

When we work with manufacturer clients, we’re typically asked to build best-in-class HUBs. But, it’s important to note that each stakeholder

Archbow Consulting worked with Pharmaceutical Executive to highlight ten pharma and biotech trends worth watching in 2018. Everything from t

FrankenLaunches happen when multiple vendors and consultants advise on different, yet interconnected elements of a brand’s launch.

Technology will undoubtedly have a positive impact on the specialty pharmaceutical business.  And, within the right context, e-services can

In our industry, crosswinds take many different forms — from scope creep to technology breakthroughs to program improvement.

Today’s marketplace has many qualified companies who operate HUBs and other patient engagement activities. It’s all they do, and they’ve put